Abstract
Cardiovascular risk factors, irregardless of their assessment modalities, are based on cardiovascular health. Lifestyle influences metabolic profiles and these changes affect cardiovascular risk factors.
Cardiovascular risk factors can be classified into three basic categories: 1. Predisposing risk factors (e.g., age, gender, medical history, and genetic factors); 2. Clinical and metabolic factors (e.g., hypertension, changes in lipid metabolism, diabetes mellitus, obesity, metabolic syndrome, homocysteine, serum uric acid concetntrations, and L-arginine dimethylated derivatives); 3. Modifying behavioral factors (e.g., cigarette smoking, high caloric diet, alcohol intake, sedentary life). Some of these factors are metabolic components of body metabolism because they act by metabolic reactions while others characterized by structural alterations of the cardiovascular system, at least initially, exert their harmful effects by metabolic substrates.
Metabolic responses such as biochemical substances, drugs or others, that act initially as cardiovascular risk factors, identify that an early treatment of the altered parameters observed should be a useful approach to reduce the rate of heart attacks with a significant improvement in the outcome of cardiovascular disease.
Keywords: Cardiovascular risk factor (s), metabolic response, heart and blood vessel rate.
Current Pharmaceutical Design
Title:Modification of Lifestyle Factors are Needed to Improve the Metabolic Health of Patients with Cardiovascular Disease Risk
Volume: 20 Issue: 39
Author(s): Linda Landini
Affiliation:
Keywords: Cardiovascular risk factor (s), metabolic response, heart and blood vessel rate.
Abstract: Cardiovascular risk factors, irregardless of their assessment modalities, are based on cardiovascular health. Lifestyle influences metabolic profiles and these changes affect cardiovascular risk factors.
Cardiovascular risk factors can be classified into three basic categories: 1. Predisposing risk factors (e.g., age, gender, medical history, and genetic factors); 2. Clinical and metabolic factors (e.g., hypertension, changes in lipid metabolism, diabetes mellitus, obesity, metabolic syndrome, homocysteine, serum uric acid concetntrations, and L-arginine dimethylated derivatives); 3. Modifying behavioral factors (e.g., cigarette smoking, high caloric diet, alcohol intake, sedentary life). Some of these factors are metabolic components of body metabolism because they act by metabolic reactions while others characterized by structural alterations of the cardiovascular system, at least initially, exert their harmful effects by metabolic substrates.
Metabolic responses such as biochemical substances, drugs or others, that act initially as cardiovascular risk factors, identify that an early treatment of the altered parameters observed should be a useful approach to reduce the rate of heart attacks with a significant improvement in the outcome of cardiovascular disease.
Export Options
About this article
Cite this article as:
Landini Linda, Modification of Lifestyle Factors are Needed to Improve the Metabolic Health of Patients with Cardiovascular Disease Risk, Current Pharmaceutical Design 2014; 20 (39) . https://dx.doi.org/10.2174/1381612820666140417094458
DOI https://dx.doi.org/10.2174/1381612820666140417094458 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Treatment-Induced Cardiotoxicity: a Cardiac Stem Cell Disease?
Cardiovascular & Hematological Agents in Medicinal Chemistry Important Aspects of Post-Prandial Antidiabetic Drug, Acarbose
Current Topics in Medicinal Chemistry Structural MRI Predictors of Late-Life Cognition Differ Across African Americans, Hispanics, and Whites
Current Alzheimer Research Role of Adiponectin in Obesity, Hypertension, and Metabolic Syndrome
Current Hypertension Reviews Meet Our Editor:
Current Hypertension Reviews Bioactivity of American Ginseng by Knockout Extract Preparation Using Monoclonal Antibody
Current Drug Discovery Technologies COVID-19: An Update on Pathogenesis and Treatment
Current Pharmaceutical Design The Effect of Serotonin 5-HT2 Receptor Inhibitor on Vasomotor Responses
Vascular Disease Prevention (Discontinued) Intravenous Thrombolysis with rt-PA in Acute Stroke Patients Aged ≥80 Years
Letters in Drug Design & Discovery Current & Future Therapies of Erectile Dysfunction in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) TRPV1 Activation Prevents Renal Ischemia-Reperfusion Injury-Induced Increase in Salt Sensitivity by Suppressing Renal Sympathetic Nerve Activity
Current Hypertension Reviews Role of Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease
Current Enzyme Inhibition High-Sensitivity C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in Predicting Recurrence and Severity of Stenosis in Symptomatic Intracranial Atherosclerotic Disease
Current Proteomics Having a Promising Efficacy on Type II Diabetes, It’s Definitely a Green Tea Time
Current Medicinal Chemistry Sleep in Pulmonary Hypertension
Current Respiratory Medicine Reviews Prevalence and Associates of Foot Deformities among Patients with Diabetes in Jordan
Current Diabetes Reviews The Impact of Body Mass Index and Type 2 Diabetes on Breast Cancer: Current Therapeutic Measures of Prevention
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Editorial [Hot Topic: Drugs Targeted to Improve Endothelial Function: Clinical Correlates Between Sexual and Internal Medicine (Executive Editor: Antonio Aversa)]
Current Pharmaceutical Design Biomarkers in Preeclamptic Women with Normoglycemia and Hyperglycemia
Current Hypertension Reviews Neurogenesis and Stroke
CNS & Neurological Disorders - Drug Targets